CHINARES PHARMA (03320) announced that its wholly-owned subsidiary, China Resources Pharmaceutical Holdings, has successfully completed the public issuance of its second tranche of 2025 corporate bonds in China. The second tranche, with a total principal of RMB1.1 billion, carries a 3-year term and an annual coupon rate of 1.78%. The net proceeds from the bond issuance will be allocated for productive expenditures, including debt repayment, working capital replenishment, project development and operational expenses, investments related to technological innovation, and other purposes compliant with applicable laws and regulations.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.